Résumé
Objective To investigate the expression of peroxisome proliferator-activated receptors (PPARs) α/δ/γ protein and the effect of berberine on them in diabetic rat kidney.Methods Type 2 diabetic rats were induced by injection (ip) with streptozotocin 35 mg·kg1 and feeding with a high-carbohydrate/high-fat diet for 16 weeks.From week 17 to 32, diabetic rats were given low, middle, high-dose berberine 75, 150, 300 mg×kg-1, fenofibrate 100 mg×kg1 and rosiglitazone 4 mg×kg-1, respectively.The expression of PPARα/δ/γ protein in kidney were detected by immunohistochemistry.Results The expression of PPARα and PPARδ protein in the kidney of diabetic rat, which were significantly higher than that of the control one (P＜0.01), while PPARγ expression was obviously lower than that of the control one (P＜0.01).The expression of PPARα and PPARδ in in diabetic kidney were increased notably after middle-dose, high-dose berberine and fenofibrate treatment (P＜0.01);middle-dose, high-dose berberine and rosiglitazone treatment significantly reduced PPARγ expression (P＜0.01).Conclusion Berberine can restore the disturbed PPARα/δ/γ protein expression in diabetic rat kidney.
Résumé
Objective To investigate the expression of peroxisome proliferator-activated receptors (PPARs) α/δ/γ protein and the effect of berberine on them in diabetic rat kidney.Methods Type 2 diabetic rats were induced by injection (ip) with streptozotocin 35 mg·kg1 and feeding with a high-carbohydrate/high-fat diet for 16 weeks.From week 17 to 32, diabetic rats were given low, middle, high-dose berberine 75, 150, 300 mg×kg-1, fenofibrate 100 mg×kg1 and rosiglitazone 4 mg×kg-1, respectively.The expression of PPARα/δ/γ protein in kidney were detected by immunohistochemistry.Results The expression of PPARα and PPARδ protein in the kidney of diabetic rat, which were significantly higher than that of the control one (P＜0.01), while PPARγ expression was obviously lower than that of the control one (P＜0.01).The expression of PPARα and PPARδ in in diabetic kidney were increased notably after middle-dose, high-dose berberine and fenofibrate treatment (P＜0.01);middle-dose, high-dose berberine and rosiglitazone treatment significantly reduced PPARγ expression (P＜0.01).Conclusion Berberine can restore the disturbed PPARα/δ/γ protein expression in diabetic rat kidney.
Résumé
Retinopathy is a major cause of morbidity in diabetes and remains the primary cause of new blindness. Therefore, it is necessary to find new drug to treat diabetic retinopathy. Type 2 diabetes mellitus (T2DM) rats were induced by injection (ip) with streptozotocin (STZ) 35 mg x kg(-1) and fed with a high-carbohydrate/high-fat diet 2 weeks later. From week 17 to 32, diabetic rats were given different doses of berberine 75, 150, and 300 mg x kg(-1), fenofibrate 100 mg x kg(-1) and rosiglitazone 4 mg x kg(-1), separately. Retinal structure was observed with hematoxylin-eosin staining and peroxisome proliferator-activated receptors (PPARs) alpha/delta/gamma protein expressions were detected by immunohistochemistry. The retina of control rats was thicker than that of other groups, 16 weeks treatment with berberine (150 and 300 mg x kg(-1)) and rosiglitazone 4 mg x kg(-1) thickened the diabetic retina, but no difference existed in retinal structure among groups. Both berberine (150 and 300 mg x kg(-1)) and rosiglitazone 4 mg x kg(-1) significantly decreased PPARy expression in diabetic retina; while berberine (150 and 300 mg x kg(-1)) and fenofibrate 100 mg x kg(-1) obviously increased both PPARalpha and PPARdelta expressions in diabetic retina. Berberine modulates PPARalpha/delta/gamma protein levels in diabetic retina which may contribute to ameliorate retinopathy complication induced by STZ and a high-carbohydrate/high-fat diet. It is expected that berberine might be a more beneficial drug to treat diabetic retinal complication comparing with fenofibrate and rosiglitazone.